aluates Reports

$ 0.0

Automative

Global Macromolecular Single-target Angiogenesis Inhibitor Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-9O18143

BUY CHAPTERS

Global Macromolecular Single-target Angiogenesis Inhibitor Market Research Report 2024

Code: QYRE-Auto-9O18143

Report

August 2024

Pages:88

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bayer

Sanofi

Eli Lilly

Roche

Amneal Pharmaceuticals

Amgen Inc

Celltrion Healthcare

Pfizer Inc

Chia Tai Tianqing

Qilu Pharma

Sinocelltech Ltd

Innovent

Jiangsu Hengrui Pharmaceuticals

Macromolecular Single-target Angiogenesis Inhibitor Market

A Macromolecular Single-target Angiogenesis Inhibitor(MSAI)is a specialized therapeutic agent designed to hinder the formation of new blood vessels,a process crucial for tumor growth and certain inflammatory diseases.By binding to VEGF or its receptors,MSIs effectively block the signals that promote blood vessel growth,thereby starving tumors of their blood supply or mitigating pathological angiogenesis.

The global Macromolecular Single-target Angiogenesis Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Macromolecular Single-target Angiogenesis Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Macromolecular Single-target Angiogenesis Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Macromolecular Single-target Angiogenesis Inhibitor include Bayer, Sanofi, Eli Lilly, Roche, Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Chia Tai Tianqing, Qilu Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Macromolecular Single-target Angiogenesis Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macromolecular Single-target Angiogenesis Inhibitor.

The Macromolecular Single-target Angiogenesis Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Macromolecular Single-target Angiogenesis Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Macromolecular Single-target Angiogenesis Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Macromolecular Single-target Angiogenesis Inhibitor Market Report

Report Metric	Details
Report Name	Macromolecular Single-target Angiogenesis Inhibitor Market
Segment by Type	Aflibercept Ramucirumab Bevacizumab Other
Segment by Application	Degenerative Eye Diseases Cancer Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bayer, Sanofi, Eli Lilly, Roche, Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Chia Tai Tianqing, Qilu Pharma, SinoCellTech, Innovent, Jiangsu Hengrui Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Macromolecular Single-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Macromolecular Single-target Angiogenesis Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Macromolecular Single-target Angiogenesis Inhibitor Market report?

Ans: The main players in the Macromolecular Single-target Angiogenesis Inhibitor Market are Bayer, Sanofi, Eli Lilly, Roche, Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Chia Tai Tianqing, Qilu Pharma, SinoCellTech, Innovent, Jiangsu Hengrui Pharmaceuticals

What are the Application segmentation covered in the Macromolecular Single-target Angiogenesis Inhibitor Market report?

Ans: The Applications covered in the Macromolecular Single-target Angiogenesis Inhibitor Market report are Degenerative Eye Diseases, Cancer, Other

What are the Type segmentation covered in the Macromolecular Single-target Angiogenesis Inhibitor Market report?

Ans: The Types covered in the Macromolecular Single-target Angiogenesis Inhibitor Market report are Aflibercept, Ramucirumab, Bevacizumab, Other

Recommended Reports

Targeted Cancer Therapies

Angiogenesis & Inhibitors

Immune & Molecular Therapy

1 Macromolecular Single-target Angiogenesis Inhibitor Market Overview

1.1 Product Definition

1.2 Macromolecular Single-target Angiogenesis Inhibitor by Type

1.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Value Comparison by Type (2024-2030)

1.2.2 Aflibercept

1.2.3 Ramucirumab

1.2.4 Bevacizumab

1.2.5 Other

1.3 Macromolecular Single-target Angiogenesis Inhibitor by Application

1.3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Value by Application (2024-2030)

1.3.2 Degenerative Eye Diseases

1.3.3 Cancer

1.3.4 Other

1.4 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size Estimates and Forecasts

1.4.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue 2019-2030

1.4.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales 2019-2030

1.4.3 Global Macromolecular Single-target Angiogenesis Inhibitor Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Macromolecular Single-target Angiogenesis Inhibitor Market Competition by Manufacturers

2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2019-2024)

2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Macromolecular Single-target Angiogenesis Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Product Type & Application

2.7 Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Date of Enter into This Industry

2.8 Global Macromolecular Single-target Angiogenesis Inhibitor Market Competitive Situation and Trends

2.8.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Macromolecular Single-target Angiogenesis Inhibitor Players Market Share by Revenue

2.8.3 Global Macromolecular Single-target Angiogenesis Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Macromolecular Single-target Angiogenesis Inhibitor Market Scenario by Region

3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2019-2030

3.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2019-2024

3.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region: 2025-2030

3.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2019-2030

3.3.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2019-2024

3.3.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2025-2030

3.4 North America Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country

3.4.1 North America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2030)

3.4.3 North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country

3.5.1 Europe Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2030)

3.5.3 Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Region

3.6.1 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2019-2030)

3.6.3 Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country

3.7.1 Latin America Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2030)

3.7.3 Latin America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Market Facts & Figures by Country

3.8.1 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2030)

3.8.3 Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2019-2030)

4.1.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2019-2024)

4.1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Type (2025-2030)

4.1.3 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2019-2030)

4.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2019-2030)

4.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2019-2024)

4.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Type (2025-2030)

4.2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2019-2030)

4.3 Global Macromolecular Single-target Angiogenesis Inhibitor Price by Type (2019-2030)

5 Segment by Application

5.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2019-2030)

5.1.1 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2019-2024)

5.1.2 Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Application (2025-2030)

5.1.3 Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2019-2030)

5.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2019-2030)

5.2.1 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2019-2024)

5.2.2 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Application (2025-2030)

5.2.3 Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2019-2030)

5.3 Global Macromolecular Single-target Angiogenesis Inhibitor Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Bayer

6.1.1 Bayer Company Information

6.1.2 Bayer Description and Business Overview

6.1.3 Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Bayer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.1.5 Bayer Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Company Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Eli Lilly

6.3.1 Eli Lilly Company Information

6.3.2 Eli Lilly Description and Business Overview

6.3.3 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.3.5 Eli Lilly Recent Developments/Updates

6.4 Roche

6.4.1 Roche Company Information

6.4.2 Roche Description and Business Overview

6.4.3 Roche Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Roche Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.4.5 Roche Recent Developments/Updates

6.5 Amneal Pharmaceuticals

6.5.1 Amneal Pharmaceuticals Company Information

6.5.2 Amneal Pharmaceuticals Description and Business Overview

6.5.3 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.5.5 Amneal Pharmaceuticals Recent Developments/Updates

6.6 Amgen

6.6.1 Amgen Company Information

6.6.2 Amgen Description and Business Overview

6.6.3 Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Amgen Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.6.5 Amgen Recent Developments/Updates

6.7 Celltrion Healthcare

6.7.1 Celltrion Healthcare Company Information

6.7.2 Celltrion Healthcare Description and Business Overview

6.7.3 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.7.5 Celltrion Healthcare Recent Developments/Updates

6.8 Pfizer

6.8.1 Pfizer Company Information

6.8.2 Pfizer Description and Business Overview

6.8.3 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.8.5 Pfizer Recent Developments/Updates

6.9 Chia Tai Tianqing

6.9.1 Chia Tai Tianqing Company Information

6.9.2 Chia Tai Tianqing Description and Business Overview

6.9.3 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.9.5 Chia Tai Tianqing Recent Developments/Updates

6.10 Qilu Pharma

6.10.1 Qilu Pharma Company Information

6.10.2 Qilu Pharma Description and Business Overview

6.10.3 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.10.5 Qilu Pharma Recent Developments/Updates

6.11 SinoCellTech

6.11.1 SinoCellTech Company Information

6.11.2 SinoCellTech Description and Business Overview

6.11.3 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.11.4 SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.11.5 SinoCellTech Recent Developments/Updates

6.12 Innovent

6.12.1 Innovent Company Information

6.12.2 Innovent Description and Business Overview

6.12.3 Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Innovent Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.12.5 Innovent Recent Developments/Updates

6.13 Jiangsu Hengrui Pharmaceuticals

6.13.1 Jiangsu Hengrui Pharmaceuticals Company Information

6.13.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview

6.13.3 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product Portfolio

6.13.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Macromolecular Single-target Angiogenesis Inhibitor Industry Chain Analysis

7.2 Macromolecular Single-target Angiogenesis Inhibitor Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Macromolecular Single-target Angiogenesis Inhibitor Production Mode & Process

7.4 Macromolecular Single-target Angiogenesis Inhibitor Sales and Marketing

7.4.1 Macromolecular Single-target Angiogenesis Inhibitor Sales Channels

7.4.2 Macromolecular Single-target Angiogenesis Inhibitor Distributors

7.5 Macromolecular Single-target Angiogenesis Inhibitor Customers

8 Macromolecular Single-target Angiogenesis Inhibitor Market Dynamics

8.1 Macromolecular Single-target Angiogenesis Inhibitor Industry Trends

8.2 Macromolecular Single-target Angiogenesis Inhibitor Market Drivers

8.3 Macromolecular Single-target Angiogenesis Inhibitor Market Challenges

8.4 Macromolecular Single-target Angiogenesis Inhibitor Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bayer

Sanofi

Eli Lilly

Roche

Amneal Pharmaceuticals

Amgen Inc

Celltrion Healthcare

Pfizer Inc

Chia Tai Tianqing

Qilu Pharma

Sinocelltech Ltd

Innovent

Jiangsu Hengrui Pharmaceuticals

List of Tables

Table 1. Global Macromolecular Single-target Angiogenesis Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Macromolecular Single-target Angiogenesis Inhibitor Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Macromolecular Single-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers in 2023

Table 4. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Macromolecular Single-target Angiogenesis Inhibitor Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Macromolecular Single-target Angiogenesis Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Product Type & Application

Table 12. Global Key Manufacturers of Macromolecular Single-target Angiogenesis Inhibitor, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Macromolecular Single-target Angiogenesis Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macromolecular Single-target Angiogenesis Inhibitor as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2019-2024) & (K Units)

Table 18. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2019-2024)

Table 19. Global Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2025-2030) & (K Units)

Table 20. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2025-2030)

Table 21. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2019-2024)

Table 23. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2025-2030)

Table 25. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2024) & (K Units)

Table 27. North America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2025-2030) & (K Units)

Table 28. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2024) & (K Units)

Table 32. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2025-2030) & (K Units)

Table 33. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) by Type (2019-2024)

Table 51. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) by Type (2025-2030)

Table 52. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2019-2024)

Table 53. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Type (2025-2030)

Table 54. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2019-2024)

Table 57. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Type (2025-2030)

Table 58. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2019-2024)

Table 59. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2025-2030)

Table 60. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) by Application (2019-2024)

Table 61. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units) by Application (2025-2030)

Table 62. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2019-2024)

Table 63. Global Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Application (2025-2030)

Table 64. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2019-2024)

Table 67. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Application (2025-2030)

Table 68. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2019-2024)

Table 69. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2025-2030)

Table 70. Bayer Company Information

Table 71. Bayer Description and Business Overview

Table 72. Bayer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Bayer Macromolecular Single-target Angiogenesis Inhibitor Product

Table 74. Bayer Recent Developments/Updates

Table 75. Sanofi Company Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Sanofi Macromolecular Single-target Angiogenesis Inhibitor Product

Table 79. Sanofi Recent Developments/Updates

Table 80. Eli Lilly Company Information

Table 81. Eli Lilly Description and Business Overview

Table 82. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Eli Lilly Macromolecular Single-target Angiogenesis Inhibitor Product

Table 84. Eli Lilly Recent Developments/Updates

Table 85. Roche Company Information

Table 86. Roche Description and Business Overview

Table 87. Roche Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Roche Macromolecular Single-target Angiogenesis Inhibitor Product

Table 89. Roche Recent Developments/Updates

Table 90. Amneal Pharmaceuticals Company Information

Table 91. Amneal Pharmaceuticals Description and Business Overview

Table 92. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Amneal Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product

Table 94. Amneal Pharmaceuticals Recent Developments/Updates

Table 95. Amgen Company Information

Table 96. Amgen Description and Business Overview

Table 97. Amgen Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Amgen Macromolecular Single-target Angiogenesis Inhibitor Product

Table 99. Amgen Recent Developments/Updates

Table 100. Celltrion Healthcare Company Information

Table 101. Celltrion Healthcare Description and Business Overview

Table 102. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Celltrion Healthcare Macromolecular Single-target Angiogenesis Inhibitor Product

Table 104. Celltrion Healthcare Recent Developments/Updates

Table 105. Pfizer Company Information

Table 106. Pfizer Description and Business Overview

Table 107. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Pfizer Macromolecular Single-target Angiogenesis Inhibitor Product

Table 109. Pfizer Recent Developments/Updates

Table 110. Chia Tai Tianqing Company Information

Table 111. Chia Tai Tianqing Description and Business Overview

Table 112. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Chia Tai Tianqing Macromolecular Single-target Angiogenesis Inhibitor Product

Table 114. Chia Tai Tianqing Recent Developments/Updates

Table 115. Qilu Pharma Company Information

Table 116. Qilu Pharma Description and Business Overview

Table 117. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Qilu Pharma Macromolecular Single-target Angiogenesis Inhibitor Product

Table 119. Qilu Pharma Recent Developments/Updates

Table 120. SinoCellTech Company Information

Table 121. SinoCellTech Description and Business Overview

Table 122. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. SinoCellTech Macromolecular Single-target Angiogenesis Inhibitor Product

Table 124. SinoCellTech Recent Developments/Updates

Table 125. Innovent Company Information

Table 126. Innovent Description and Business Overview

Table 127. Innovent Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Innovent Macromolecular Single-target Angiogenesis Inhibitor Product

Table 129. Innovent Recent Developments/Updates

Table 130. Jiangsu Hengrui Pharmaceuticals Company Information

Table 131. Jiangsu Hengrui Pharmaceuticals Description and Business Overview

Table 132. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Jiangsu Hengrui Pharmaceuticals Macromolecular Single-target Angiogenesis Inhibitor Product

Table 134. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Macromolecular Single-target Angiogenesis Inhibitor Distributors List

Table 138. Macromolecular Single-target Angiogenesis Inhibitor Customers List

Table 139. Macromolecular Single-target Angiogenesis Inhibitor Market Trends

Table 140. Macromolecular Single-target Angiogenesis Inhibitor Market Drivers

Table 141. Macromolecular Single-target Angiogenesis Inhibitor Market Challenges

Table 142. Macromolecular Single-target Angiogenesis Inhibitor Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Macromolecular Single-target Angiogenesis Inhibitor

Figure 2. Global Macromolecular Single-target Angiogenesis Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Macromolecular Single-target Angiogenesis Inhibitor Market Share by Type: 2023 & 2030

Figure 4. Aflibercept Product Picture

Figure 5. Ramucirumab Product Picture

Figure 6. Bevacizumab Product Picture

Figure 7. Other Product Picture

Figure 8. Global Macromolecular Single-target Angiogenesis Inhibitor Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global Macromolecular Single-target Angiogenesis Inhibitor Market Share by Application: 2023 & 2030

Figure 10. Degenerative Eye Diseases

Figure 11. Cancer

Figure 12. Other

Figure 13. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size (2019-2030) & (US$ Million)

Figure 15. Global Macromolecular Single-target Angiogenesis Inhibitor Sales (2019-2030) & (K Units)

Figure 16. Global Macromolecular Single-target Angiogenesis Inhibitor Average Price (US$/Unit) & (2019-2030)

Figure 17. Macromolecular Single-target Angiogenesis Inhibitor Report Years Considered

Figure 18. Macromolecular Single-target Angiogenesis Inhibitor Sales Share by Manufacturers in 2023

Figure 19. Global Macromolecular Single-target Angiogenesis Inhibitor Revenue Share by Manufacturers in 2023

Figure 20. Global 5 and 10 Largest Macromolecular Single-target Angiogenesis Inhibitor Players: Market Share by Revenue in Macromolecular Single-target Angiogenesis Inhibitor in 2023

Figure 21. Macromolecular Single-target Angiogenesis Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 22. Global Macromolecular Single-target Angiogenesis Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2019-2030)

Figure 24. North America Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2019-2030)

Figure 25. United States Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2019-2030)

Figure 28. Europe Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2019-2030)

Figure 29. Germany Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Region (2019-2030)

Figure 36. China Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2019-2030)

Figure 44. Mexico Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Colombia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Sales Market Share by Country (2019-2030)

Figure 49. Middle East and Africa Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Country (2019-2030)

Figure 50. Turkey Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE Macromolecular Single-target Angiogenesis Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of Macromolecular Single-target Angiogenesis Inhibitor by Type (2019-2030)

Figure 54. Global Revenue Market Share of Macromolecular Single-target Angiogenesis Inhibitor by Type (2019-2030)

Figure 55. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Type (2019-2030)

Figure 56. Global Sales Market Share of Macromolecular Single-target Angiogenesis Inhibitor by Application (2019-2030)

Figure 57. Global Revenue Market Share of Macromolecular Single-target Angiogenesis Inhibitor by Application (2019-2030)

Figure 58. Global Macromolecular Single-target Angiogenesis Inhibitor Price (US$/Unit) by Application (2019-2030)

Figure 59. Macromolecular Single-target Angiogenesis Inhibitor Value Chain

Figure 60. Macromolecular Single-target Angiogenesis Inhibitor Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024

Global Single target Anti VEGF Drugs Market Research Report 2024

Global Fusion Protein VEGF Inhibitor Market Research Report 2024

Bevacizumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global VEGF Inhibitors for Cancer Market Research Report 2024

Global Antiangiogenic Drugs Market Research Report 2024

Global VEGFR 2 Inhibitor Market Research Report 2024

Global VEGF Inhibitors Market Research Report 2024

Global Multitarget Inhibitor Market Research Report 2024

VEGF Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Vascular Endothelial Growth Factor VEGF Inhibitors Market Insights Forecast to 2030

Global VEGF A Inhibitor Market Research Report 2024

Global Cancer Angiogenesis Inhibitors Market Research Report 2024

Global Angiogenesis Therapeutic Agent Market Research Report 2024

Multikinase Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Small Molecule Targeted Cancer Therapy Market Research Report 2025

Global Single target MET TKIs Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions